TuHURA Biosciences Q1 2026 Earnings Report

TuHURA Biosciences EPS Results

• Actual EPS: -$0.13
• Consensus EPS: -$0.12
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: N/A

TuHURA Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

TuHURA Biosciences Announcement Details

• Quarter: Q1 2026
• Date: 5/15/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

TuHURA Biosciences (NASDAQ:HURA) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states. This platform enables the identification of previously unrecognized biological pathways and target proteins, supporting both small‐molecule and biologic drug discovery. The technology is designed to accelerate early‐stage research by revealing disease drivers that traditional genomics and transcriptomics methods may overlook.

TuHURA is advancing a pipeline of programs in areas such as immunology, neurodegeneration and female health. The company has entered research collaborations with pharmaceutical and academic partners to validate targets and co‐develop lead candidates. These partnerships are helping TuHURA expand its reach into therapeutic areas of high unmet medical need while leveraging external expertise and resources.

Founded as a spin‐out from the University of California, Davis technology transfer office, TuHURA Biosciences is headquartered in California and serves a global research community. The company completed its initial public offering on the Nasdaq Capital Market under the ticker HURA in 2022, positioning itself for continued growth and innovation in proteomics‐driven drug discovery.